SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
OrbiMed files Amendment No. 5 to a Schedule 13G/A reporting ownership in SI-BONE, Inc. (SIBN). OrbiMed Capital LLC reports beneficial ownership of 2,184,200 shares, representing 5.1% of SI-BONE's common stock, with sole voting and dispositive power over those shares. OrbiMed Advisors LLC reports beneficial ownership of 394,779 shares, representing 0.9%, with shared voting and dispositive power. Together the reporting persons hold 6.0% of the class on behalf of other persons and exercise investment and voting power through a management committee of three named members. The filing states the shares were acquired in the ordinary course of business and not for the purpose of changing control.
Champlain Investment Partners, LLC reported beneficial ownership of 2,140,074 shares of SI-BONE, Inc. common stock, representing 5.0% of the outstanding class. The filing states Champlain is organized in Vermont and acts as an investment adviser.
The report breaks down voting and dispositive power: 1,368,619 shares are listed as sole voting power and 2,140,074 shares as sole dispositive power. The filer certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
John G. Freund, a director of SI-BONE, Inc. (SIBN), reported insider sales and remaining holdings. The Form 4 shows a sale (Code S) of 12,132 shares on 08/08/2025 at a weighted-average price of $15.9906, executed in multiple trades with prices ranging from $15.80 to $16.3950. The filing also records a reported disposition of 43,301 shares which includes 8,675 restricted stock units.
The report shows 91,767 shares beneficially owned following the reported transaction(s), held indirectly by John Freund Family Partnership IV, L.P. The filing notes the Reporting Person is a general partner of that Family LP and disclaims beneficial ownership except to the extent of pecuniary interest.
SI-BONE (SIBN) – Form 4 insider transaction
Director Jeffrey W. Dunn executed an automatic “sell-to-cover” on 08/04/2025 related to the vesting of restricted stock units. To satisfy tax-withholding, he sold 293 common shares at a weighted-average price of $17.3743 (price range $17.36-$17.39). The sale was executed under Rule 10b5-1 and is classified as code “S”, indicating a non-discretionary sale for tax purposes.
Post-transaction holdings are 11,647 shares held directly and 117,827 shares held indirectly via The Jeffrey W. Dunn Living Trust. The indirect total includes 11,124 un-settled RSUs. No derivative securities were reported.
The transaction represents less than 0.1% of Dunn’s aggregate ownership and does not signal a strategic shift or change in insider sentiment.
SI-BONE, Inc. (SIBN) – Form 4 filing dated 07/07/2025
Senior Vice President, Operations & Administration and Chief Legal Officer Michael A. Pisetsky reported a routine “sell-to-cover” transaction tied to the vesting of restricted stock units (RSUs) on 07/02/2025. To satisfy withholding taxes, Pisetsky sold an aggregate 3,127 common shares in three market transactions at weighted-average prices between $18.26 – $18.38 per share.
Following the sales, the executive retains 261,681 common shares, which includes 145,043 shares underlying un-settled RSUs. No derivative securities were involved, and the filing states the sales were non-discretionary and solely for tax purposes.
The disposition represents approximately 1.2 % of the executive’s post-transaction holdings and does not alter overall insider ownership meaningfully. There is no indication of strategic intent or change in outlook for SIBN; the filing is considered administratively routine under Section 16 rules.